BioNotebook: Seattle Genetics/AbbVie, Auspex, Flexion, Ironwood
This article was originally published in Scrip
AbbVie extends Seattle Genetics collaboration; Auspex raises $35m; Flexion files for $86m IPO; and Ironwood makes 10% jobs cut.
You may also be interested in...
Seattle Genetics is transitioning from a one-product to multi-product company while growing its established Adcetris franchise. New studies are coming for three additional antibody-drug conjugates aimed at solid tumors.
Antibody-drug conjugates have taken a back seat to cancer immunotherapy as the hot modality in oncology of late, but AbbVie Inc. and CytomX Therapeutics Inc. unveiled a partnership on April 20 to develop an ADC in a deal that CytomX cites as further validation of its Probody technology platform.
Italfarmaco’s HDAC inhibitor helped ambulatory Duchenne muscular dystrophy patients climb stairs faster than non-treated boys while Capricor’s cell therapy improved upper limb function in non-ambulatory patients.